Skip to content

BridgeBio Pharma BBIO Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
ALN
Alnylam PharmaceuticalsALNY
Roivant Sciences logo
Roivant SciencesROIV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's common stock, shares issued (in shares)?
BridgeBio Pharma (BBIO) reported common stock, shares issued (in shares) of $204.39M in Q1 2026.